Eleftha 150mg Injection

About Eleftha 150mg Injection

Eleftha 150 mg Injection contains trastuzumab, a monoclonal antibody used to treat HER2-positive breast and gastric cancers. It works by specifically targeting the HER2 protein on cancer cells, blocking signals that promote uncontrolled cell growth and helping slow the progression of the disease. By binding to the HER2 receptor, Eleftha supports targeted cancer therapy with improved treatment outcomes.

Eleftha is administered as an intravenous (IV) infusion by a healthcare professional, usually weekly or every three weeks depending on the treatment plan. Common side effects include fever, headache, cough, rash, infections, and sleep disturbances, while serious risks may include heart problems, allergic reactions, or lung complications. Heart function and vital signs are closely monitored during treatment, and use during pregnancy is not recommended without strict medical advice.